Eosinopenia predicts poor outcomes in patients with lung cancer with the omicron variant of COVID-19
BackgroundLung cancer is among the malignancies most vulnerable to coronavirus disease 2019 (COVID-19). Eosinophils have anti-tumor and antiviral effects. Since November 2021, the omicron variant of COVID-19 has become a topic of concern; however, the impact of eosinophils on the severity and outcom...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1583843/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850095033591529472 |
|---|---|
| author | Xiao Hu Jie Tan Rumei Luan Rumei Luan Dongyan Ding Dongyan Ding Ming Yue Junling Yang Qianfei Xue |
| author_facet | Xiao Hu Jie Tan Rumei Luan Rumei Luan Dongyan Ding Dongyan Ding Ming Yue Junling Yang Qianfei Xue |
| author_sort | Xiao Hu |
| collection | DOAJ |
| description | BackgroundLung cancer is among the malignancies most vulnerable to coronavirus disease 2019 (COVID-19). Eosinophils have anti-tumor and antiviral effects. Since November 2021, the omicron variant of COVID-19 has become a topic of concern; however, the impact of eosinophils on the severity and outcomes of patients with lung cancer with omicron remains uncertain. This study aimed to utilize eosinophils to predict patient outcomes and guide the prevention and monitoring of omicron.MethodsThis study performed an analysis of 284 patients with lung cancer who were hospitalized in the second hospital of Jilin University, of whom 83 patients were confirmed to have omicron infection. Depending on the eosinophil counts, patients were divided into two groups: low and high eosinophil counts. The relationship between eosinophil counts and severity and outcomes was then analyzed.ResultsWe found that omicron, especially severe-to-critical omicron, decreased survival in patients with lung cancer. Patients with omicron had a lower eosinophil count. Patients with eosinopenia (< 0.015 × 109/L) were more likely to have an eastern cooperative oncology group performance status ≥ 2; be undergoing anti-cancer treatment; have comorbidities; and exhibit lower disease control rates, reduced 30-day survival, and shorter overall survival (median 75 days vs. not reached). Multivariate regression analysis revealed that the eosinophil count was an independent predictor of disease severity and survival in patients with lung cancer with omicron.ConclusionEosinopenia correlates with poor outcomes in patients with lung cancer with omicron, and the eosinophil count is an independent indicator for predicting the severity and outcomes in these patients. |
| format | Article |
| id | doaj-art-d0532aa92c154fdc8b575660ee052c1a |
| institution | DOAJ |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-d0532aa92c154fdc8b575660ee052c1a2025-08-20T02:41:32ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-07-011210.3389/fmed.2025.15838431583843Eosinopenia predicts poor outcomes in patients with lung cancer with the omicron variant of COVID-19Xiao Hu0Jie Tan1Rumei Luan2Rumei Luan3Dongyan Ding4Dongyan Ding5Ming Yue6Junling Yang7Qianfei Xue8Department of Respiratory Medicine, The Second Hospital of Jilin University, Changchun, ChinaDepartment of Respiratory Medicine, The Second Hospital of Jilin University, Changchun, ChinaDepartment of Respiratory Medicine, The Second Hospital of Jilin University, Changchun, ChinaShandong First Medical University Affiliated Provincial Hospital, Jinan, Shandong, ChinaDepartment of Respiratory Medicine, The Second Hospital of Jilin University, Changchun, ChinaDepartment of Pulmonary and Critical Care Medicine of Jiangbei Campus, The First Affiliated Hospital of Army Medical University, Chongqing, ChinaDepartment of Respiratory Medicine, The Second Hospital of Jilin University, Changchun, ChinaDepartment of Respiratory Medicine, The Second Hospital of Jilin University, Changchun, ChinaDepartment of Internal Medicine, Hospital of Jilin University, Changchun, ChinaBackgroundLung cancer is among the malignancies most vulnerable to coronavirus disease 2019 (COVID-19). Eosinophils have anti-tumor and antiviral effects. Since November 2021, the omicron variant of COVID-19 has become a topic of concern; however, the impact of eosinophils on the severity and outcomes of patients with lung cancer with omicron remains uncertain. This study aimed to utilize eosinophils to predict patient outcomes and guide the prevention and monitoring of omicron.MethodsThis study performed an analysis of 284 patients with lung cancer who were hospitalized in the second hospital of Jilin University, of whom 83 patients were confirmed to have omicron infection. Depending on the eosinophil counts, patients were divided into two groups: low and high eosinophil counts. The relationship between eosinophil counts and severity and outcomes was then analyzed.ResultsWe found that omicron, especially severe-to-critical omicron, decreased survival in patients with lung cancer. Patients with omicron had a lower eosinophil count. Patients with eosinopenia (< 0.015 × 109/L) were more likely to have an eastern cooperative oncology group performance status ≥ 2; be undergoing anti-cancer treatment; have comorbidities; and exhibit lower disease control rates, reduced 30-day survival, and shorter overall survival (median 75 days vs. not reached). Multivariate regression analysis revealed that the eosinophil count was an independent predictor of disease severity and survival in patients with lung cancer with omicron.ConclusionEosinopenia correlates with poor outcomes in patients with lung cancer with omicron, and the eosinophil count is an independent indicator for predicting the severity and outcomes in these patients.https://www.frontiersin.org/articles/10.3389/fmed.2025.1583843/fullomicronCOVID-19lung cancereosinopeniaoutcomes |
| spellingShingle | Xiao Hu Jie Tan Rumei Luan Rumei Luan Dongyan Ding Dongyan Ding Ming Yue Junling Yang Qianfei Xue Eosinopenia predicts poor outcomes in patients with lung cancer with the omicron variant of COVID-19 Frontiers in Medicine omicron COVID-19 lung cancer eosinopenia outcomes |
| title | Eosinopenia predicts poor outcomes in patients with lung cancer with the omicron variant of COVID-19 |
| title_full | Eosinopenia predicts poor outcomes in patients with lung cancer with the omicron variant of COVID-19 |
| title_fullStr | Eosinopenia predicts poor outcomes in patients with lung cancer with the omicron variant of COVID-19 |
| title_full_unstemmed | Eosinopenia predicts poor outcomes in patients with lung cancer with the omicron variant of COVID-19 |
| title_short | Eosinopenia predicts poor outcomes in patients with lung cancer with the omicron variant of COVID-19 |
| title_sort | eosinopenia predicts poor outcomes in patients with lung cancer with the omicron variant of covid 19 |
| topic | omicron COVID-19 lung cancer eosinopenia outcomes |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1583843/full |
| work_keys_str_mv | AT xiaohu eosinopeniapredictspooroutcomesinpatientswithlungcancerwiththeomicronvariantofcovid19 AT jietan eosinopeniapredictspooroutcomesinpatientswithlungcancerwiththeomicronvariantofcovid19 AT rumeiluan eosinopeniapredictspooroutcomesinpatientswithlungcancerwiththeomicronvariantofcovid19 AT rumeiluan eosinopeniapredictspooroutcomesinpatientswithlungcancerwiththeomicronvariantofcovid19 AT dongyanding eosinopeniapredictspooroutcomesinpatientswithlungcancerwiththeomicronvariantofcovid19 AT dongyanding eosinopeniapredictspooroutcomesinpatientswithlungcancerwiththeomicronvariantofcovid19 AT mingyue eosinopeniapredictspooroutcomesinpatientswithlungcancerwiththeomicronvariantofcovid19 AT junlingyang eosinopeniapredictspooroutcomesinpatientswithlungcancerwiththeomicronvariantofcovid19 AT qianfeixue eosinopeniapredictspooroutcomesinpatientswithlungcancerwiththeomicronvariantofcovid19 |